Microbix Biosystems: presentation of data on respiratory virus controls at two events

MISSISSAUGA, CANADA, April 19, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer and exporter, announces that it will present the performance results of its quality assessment products (“QAP™”) that support molecular diagnostics (“MDx“) Respiratory Virus Testing at Two Industry Conventions – “Laboratory Quality Days” in Helsinki, Finland on April 20 and 21, 2022 and “ECCMID 2022” in Lisbon, Portugal, from April 23 to 26, 2022.

Labquality Days is an annual international congress focusing on quality in laboratory medicine and medical devices. It is sponsored by Labquality Oy, a well-established Scandinavian clinical laboratory competence and accreditation authority that is also a Microbix distribution partner. ECCMID 2022 is on the 32n/a annual congress organized by the European Society of Clinical Microbiology and Infectious Diseases.

At these events, Microbix will present the performance results of its QAPs for supporting MDx assays that detect multiple respiratory viruses from a single patient sample. At Labquality Days, Microbix’s presentation is titled “Multi-platform compatible multiplex respiratory virus samples from Microbix for use as a quality management tool in syndromic laboratory testing.” At ECCMID, the presentation of Microbix is ​​called “Multiplex formulations of respiratory viruses dried on Copan’s FLOQSwab® for use as cross-platform compatible EQA samples and laboratory quality controls.“Microbix would like to thank its six collaborating firms for their assistance in planning and conducting these reviews. The posters will be available on the Microbix website (https://microbix.com) following their presentation.

The two poster presentations detail the performance of three Microbix “multiplex” QAPs that each support testing for three to four pathogens, collectively providing testing quality management support for 11 common respiratory viruses – adenoviruses, enterovirus, influenza A, influenza B, metapneumovirus, parainfluenza 2, Parainfluenza 3, respiratory syncytial virus, rhinovirus, SARS-CoV-2 (aka COVID-19) and seasonal coronavirus OC43. Each of these 11 viruses continues to cause widespread human disease.

These QAPs support next-generation diagnostics that simultaneously detect multiple pathogens from a single patient sample – called “multiplex“. By establishing the precise cause of disease symptoms, multiplex tests help improve patient care while providing public health with information on institutional or community prevalence of pathogens. Several new MDx multiplex tests are also suitable for use outside of clinical laboratories – point-of-care (“COP“) sites such as clinics or pharmacies – and thus provide easier access to care and faster test results. Microbix “PROCEEDx™FLOQ®” and “REDx™FLOQ®“QAPs formatted on Copan® FLOQSwabs® are ideal for supporting POC testing, as they fully emulate testing workflows and are stable at room temperature.

Purchase requests for Microbix QAPs can be emailed to [email protected]

About Microbix Biosystems

Microbix develops proprietary biological technology solutions for human health and well-being, with over 100 skilled employees and sales now approaching C$2.0 million per month. It manufactures a wide range of critical biological materials for the global diagnostics industry, including antigens for immunoassays and its Quality Laboratory Assessment Products (QAPs™) that support clinical laboratory proficiency testing, enable the development and validation of tests, or help ensure the quality of clinical diagnosis. workflow. Microbix antigens enable antibody testing from more than 100 international diagnostic companies, while its QAPs are sold to clinical laboratory accreditation bodies, diagnostic companies and clinical laboratories. Microbix QAPs are now available in over 30 countries, distributed by 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International Distribution SpA., Labquality Oy, The Medical Supply Company of Ireland, R-Biopharm AG , SDT Molecular Pte Ltd, Seegene Canada Inc. and Thomas Scientific LLC. Microbix is ​​ISO 9001 and 13485 accredited, registered with the US FDA, registered with the Australian TGA, approved by Health Canada and provides CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, including Viral Transport Medium (DxTM™) to stabilize patient samples for molecular diagnostic laboratory testing and Kinlytic® Urokinase, a biological thrombolytic drug used to treat blood clots. . Microbix is ​​listed on the TSX and OTCQX and is headquartered in Mississauga, Ontario, Canada.

Forward-looking information

This press release contains “forward-looking information”, as that term is defined in applicable securities laws. Forward-looking information includes, but is not limited to, discussions of Labquality Days, Labquality or ECCMID 2022, posters or their relevance, products of Microbix or its associates, Microbix’s business activities and results, objectives or outlook, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including controlling costs, quality, quantity and delivery times), foreign currencies and exchange rates, maintaining adequate working capital or raising additional capital on terms acceptable or not to the any, and other similar statements regarding anticipated future events, conditions or results that are not facts historical. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied by the forward-looking information. All statements are made as of the date of this press release and represent the judgment of the Company as of the date of this new press release, and the Company undertakes no obligation to update or change any forward-looking information.

Please visit https://microbix.com or www.sedar.com for the latest Microbix news and filings.

For more information, please contact Microbix at:

Cameron Groome, CEO

(905) 361-8910

Jim Currie,


(905) 361-8910

Deborah Honig,

Investor Relations

Adelaide Capital Markets

(647) 203-8793 [email protected]

Jim McDonald,

Investor Relations

Capital of the Torrey Hills

(858) 456-7300

[email protected]

Copyright © 2022 Microbix Biosystems Inc.

Microbix®, DxTM™, Kinlytic® and QAPs™ are registered trademarks of Microbix Biosystems Inc.

PROCEEDx™FLOQ® and REDx™FLOQ® are registered trademarks of Microbix Biosystems Inc. in collaboration with Copan Italia SpA

Copan®, FLOQ® and FLOQSwab® are registered trademarks of Copan Italia SpA

James V. Hayes